Applied therapeutics stock.

Feb 15, 2024 ... Applied Therapeutics Inc (NASDAQ:APLT) shares are trading higher after the company, on Thursday, released interim 12-month results from the ...Understanding stock price lookup is a basic yet essential requirement for any serious investor. Whether you are investing for the long term or making short-term trades, stock price...2.3800 -0.07 (-2.86%) After hours: 08:00PM EST. Time Period: Jan 17, 2023 - Jan 17, 2024. Show: Historical Prices. Frequency: Daily. Apply. Currency in USD Download. Loading …Jan 3, 2022 · Shares of Applied Therapeutics ( APLT 2.50%), a clinical-stage biopharmaceutical company, are sliding today in response to upsetting news regarding its lead candidate. It turns out the Food and ...

Applied Therapeutics Inc stock performance at a glance. Check Applied Therapeutics Inc’s past financial performance, like revenue or net income, plus the top level summary of its past and current market value. APLT Stock Performance. USD USD; Previous close: 3.75: 3.75: Day range: 3.73 - 5.833.73 - 5.83Year range: 0 - 50 - 5Jan 5, 2024 ... Applied Therapeutics' stock market winning streak has come to an end. Having seen its shares soar over the past year, the biotech suffered a ...

Feb 16, 2024 · Applied Therapeutics' phase 3 INSPIRE study using govorestat for treatment of patients with SORD deficiency achieved. Read why I rate APLT stock a buy. In health-care professions, “therapeutic use of self” describes the ability of a caregiver to use his or her personality “consciously and in full awareness in an attempt to establi...

Applied Therapeutics, Inc. (“Applied Therapeutics”) (NASDAQ-GM: APLT) recently completed an underwritten public offering of 3450000 shares of its common ...Feb 16, 2024 · Applied Therapeutics (APLT) stock hit a new 52-week high as data from the biotech's Phase 3 INSPIRE trial for lead drug continued to impress investors. Read more here. Applied Therapeutics Stock Prediction 2030. In 2030, the Applied Therapeutics stock will reach $ 123.87 if it maintains its current 10-year average growth rate. If this Applied Therapeutics stock prediction for 2030 materializes, APLT stock willgrow 2,539.43% from its current price. Company profile page for Applied Therapeutics Inc including stock price, company news, executives, ... Applied Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company.Applied Therapeutics Inc. analyst ratings, historical stock prices, ... Actuals & Estimates Applied Therapeutics Inc. Quarterly; Annual; Actual Analyst Range Consensus. 0.20 0.00-0.20-0.40. Actual ...

Feb 16, 2024 · Applied Therapeutics stock rises on EMA orphan drug status for metabolic disorder drug AT-007 SA News Fri, Jun. 03, 2022 1 Comment Applied Therapeutics GAAP EPS of -$0.88

In today’s fast-paced world, finding activities that provide relaxation and a sense of accomplishment is more important than ever. One such activity that has gained popularity in r...

APLT - Applied Therapeutics Inc Stock Price and Quote. Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools. APLT. Applied …NEW YORK, June 22, 2022 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (NASDAQ: APLT) (the “Company”), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates ...Stock Price & Overview. 1.62K followers. $5.13 -0.18 ( -3.39%) 4:00 PM 02/21/24. NASDAQ | $USD | Pre-Market: $5.40 +0.27 (+5.26%) 7:32 AM. Summary. Ratings. Financials. …5 days ago · According to the issued ratings of 1 analysts in the last year, the consensus rating for Applied Therapeutics stock is Buy based on the current 1 buy rating for APLT. The average twelve-month price prediction for Applied Therapeutics is $10.50 with a high price target of $14.00 and a low price target of $7.00. Applied Therapeutics Announces MAA Validation and NDA Submission of Govorestat (AT-007) for Treatment of Classic Galactosemia. Find the latest Applied Therapeutics, Inc. (APLT) stock quote ... 3 days ago · According to 3 analysts, the average rating for APLT stock is "Strong Buy." The 12-month stock price forecast is $11.0, which is an increase of 96.43% from the latest price. Price Target $11.0 ( 96.43% upside) Analyst Consensus: Strong Buy Stock Forecasts News All Videos Press Releases Conversation

Jan 5, 2024 · Applied Therapeutics (NASDAQ:APLT) stock is falling on Friday following the release of Phase 3 clinical trial data from the clinical-stage biopharmaceutical company. Apr 24, 2023 · Applied Therapeutics, Inc. Announces $30 Million Private Placement of Equity. NEW YORK, April 24, 2023 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (NASDAQ: APLT) (the “Company”), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet ... Applied Therapeutics Inc stock performance at a glance. Check Applied Therapeutics Inc’s past financial performance, like revenue or net income, plus the top level summary of its past and current market value. APLT Stock Performance. USD USD; Previous close: 3.75: 3.75: Day range: 3.73 - 5.833.73 - 5.83Year range: 0 - 50 - 5Find the latest Applied Therapeutics, Inc. (APLT) stock quote, history, news and other vital information to help you with your stock trading and investing.With Applied Therapeutics stock trading at $3.12 per share, the total value of Applied Therapeutics stock (market capitalization) is $240.96M. Applied Therapeutics stock was originally listed at a price of $9.40 in May 14, 2019. If you had invested in Applied Therapeutics stock at $9.40, your return over the last 4 years would have been -66.81% ...

NEW YORK, June 22, 2022 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (NASDAQ: APLT) (the “Company”), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced the pricing of its underwritten public offering of …Applied Therapeutics Inc (NASDAQ: APLT) released topline results of the ARISE-HF Phase 3 trial of AT-001 (caficrestat) in patients with Diabetic Cardiomyopathy (DbCM) at high risk of

Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most. Discover our process ». Information on stock, financials, earnings, subsidiaries, investors, and executives for Applied Therapeutics. Use the PitchBook Platform to explore the full profile.Feb 16, 2024 · Applied Therapeutics' phase 3 INSPIRE study using govorestat for treatment of patients with SORD deficiency achieved. Read why I rate APLT stock a buy. NEW YORK, April 24, 2023 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced results from the ACTION-Galactosemia Kids study of govorestat (AT …545 Fifth Ave. Suite 1400, New York, NY 10017. Where is Applied Therapeutics incorporated? When was Applied Therapeutics founded? Which stock exchange are Applied Therapeutics shares traded on and what is the company’s ticker? When did the company go public? Who is Applied Therapeutics’ transfer agent? What is Applied …EAM Investors LLC purchased a new position in Applied Therapeutics, Inc. (NASDAQ:APLT - Free Report) in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 391,595 shares of the company's stock, valued at approxAT-007 for Galactosemia. AT-007 is a once-daily oral compound that inhibits the enzyme Aldose Reductase. Aldose Reductase plays a crucial role in the pathogenesis of Galactosemia. Galactosemia is a rare, slowly progressing metabolic disease caused by a genetic inability to break down the sugar galactose. Aldose Reductase converts …Feb 16, 2024 · Applied Therapeutics (APLT) stock hit a new 52-week high as data from the biotech's Phase 3 INSPIRE trial for lead drug continued to impress investors. Read more here. Applied Therapeutics Inc Stock Earnings. The value each APLT share was expected to gain vs. the value that each APLT share actually gained. APLT ( APLT) reported Q3 2023 earnings per share (EPS) of -$0.47, missing estimates of -$0.24 by 91.28%. In the same quarter last year, APLT 's earnings per share (EPS) was -$0.40.

Applied Therapeutics Inc. Applied Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company was founded by Shoshana Shendelman on January 20, 2016 and is headquartered in New York, NY.

AT-007 for Galactosemia. AT-007 is a once-daily oral compound that inhibits the enzyme Aldose Reductase. Aldose Reductase plays a crucial role in the pathogenesis of Galactosemia. Galactosemia is a rare, slowly progressing metabolic disease caused by a genetic inability to break down the sugar galactose. Aldose Reductase converts …

The Investor Relations website contains information about Applied Therapeutics's business for stockholders, potential investors, and financial analysts. Applied Therapeutics-stock. Applied Therapeutics Inc Registered Shs Stock , APLT. 2.99 -0.03 -1.02% 03:21:32 PM. NAS. Add to watchlist. News. Analyst …Applied Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need.Feb 15, 2024 ... Currently, Applied Therapeutics stock is climbing 16.04 percent, to $3.11 over the previous close of $2.68 on a volume of 3,752,156. It had ...Feb 15, 2024 · Applied Therapeutics ( NASDAQ: APLT) rose ~14% premarket Thursday after the biotech said its Phase 3 INSPIRE trial for lead candidate govorestat (AT-007) reached main goals against a rare ... See Applied Therapeutics, Inc. (APLT) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades. Career Opportunities. At Applied Therapeutics, we are passionate about our mission to develop transformative treatments for patients with high unmet medical need. Applied Therapeutics is dynamic company built on the foundational values of trust, respect, empathy, creativity, quality, integrity and collaboration. Our team is exactly that – a ...Applied Therapeutics (APLT) sotck rises as its late-stage trial for lead asset govorestat hits main goals in Sorbitol Dehydrogenase ((SORD)) Deficiency. Read more here.Diversity & Inclusion. At Applied Therapeutics, our success and ability to develop life-changing treatments for patients requires a diverse and inclusive workforce. Our company promotes an environment of diversity and inclusiveness, regardless of race, gender, sexual orientation, religion, ethnicity, national origin, physical disability, or age.

Short interest for Applied Therapeutics gives investors a sense of the degree to which investors are betting on the decline of Applied Therapeutics's stock. Short interest data is updated every ... Applied Therapeutics (APLT) sotck rises as its late-stage trial for lead asset govorestat hits main goals in Sorbitol Dehydrogenase ((SORD)) Deficiency. Read more here.Future criteria checks 2/6. Applied Therapeutics is forecast to grow earnings and revenue by 14% and 79.2% per annum respectively. EPS is expected to grow by 22.3% per annum. Return on equity is forecast to be -229.5% in 3 years.Instagram:https://instagram. trowe price comrenta cerca de mi ubicacionlee greenwood songscity bike rental chicago Find out the direct holders, institutional holders and mutual fund holders for Applied Therapeutics, Inc. (APLT). lovely miminepal market near me Applied Therapeutics stock is tumbling on Friday as investors react to lackluster results from a Phase 3 clinical trial of AT-001.More From InvestorPlace The #1 AI Investment Might Be This Company ... peinados elegantes Find the latest Applied Therapeutics, Inc. (APLT) stock quote, history, news and other vital information to help you with your stock trading and investing.A high-level overview of Applied Therapeutics, Inc. (APLT) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. Applied Therapeutics Inc (NASDAQ: APLT) has reported initial biomarker data from the pediatric ACTION-Galactosemia Kids study and baseline analysis of the 47 children enrolled in the study.